Login
$AUPH
$15.40 -$0.08 (0.52%) After hours

$AUPH 8-K SEC Filings

Filed On Filing
30 Oct 2026 8-K: Results of Operations and Financial Condition

EDMONTON, Alberta – October 30, 2026 – Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced financial results for the three and nine months ended September 30, 2026 and provided an update on recent business progress.

19 Aug 2026 8-K: Other Events

EDMONTON, Alberta – August 19, 2026 – Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced that it and its subsidiary, Aurinia Pharma U.S., Inc., (collectively, “Aurinia”) have entered into a settlement agreement with Teva Pharmac...

06 Aug 2026 8-K: Results of Operations and Financial Condition

Aurinia Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 2026 and Provides Update on Recent Business Progress

04 Jun 2026 8-K: Submission of Matters to a Vote of Security Holders

(a)Aurinia Pharmaceuticals Inc. (the "Corporation") held its annual general meeting of shareholders virtually on June 3, 2026 (the "2026 Meeting").

11 May 2026 8-K: Completion of Acquisition or Disposition of Assets

As previously disclosed by Aurinia Pharmaceuticals Inc. (“Ultimate Parent” or “Aurinia”) in its Current Report on Form 8-K filed with the Securities and Exchange Commission (the “SEC”) on April 3, 2026, Aurinia Pharma U.S., Inc., a Delaw...

07 May 2026 8-K: Results of Operations and Financial Condition

Aurinia Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2026 and Provides Update on Recent Business Progress

03 Apr 2026 8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure

Exhibit 2.1 AGREEMENT AND PLAN OF MERGER BY AND AMONG AURINIA PHARMA U.S., INC., a Delaware corporation; AURINIA MERGER SUB, INC., a Delaware corporation; KEZAR LIFE SCIENCES, INC., a Delaware corporation; AND solely for purposes of Sect...

23 Mar 2026 8-K: Departure/Election of Directors or Officers; Compensation

ROCKVILLE, Maryland and EDMONTON, Alberta – March 23, 2026 – Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) announced today that Kevin Tang, Aurinia’s Chair of the Board, will succeed Peter Greenleaf as Chief Executive Officer. Peter will c...

26 Feb 2026 8-K: Results of Operations and Financial Condition

Aurinia Pharmaceuticals Reports Financial Results for the Three and Twelve Months Ended December 31, 2025 and Provides Update on Recent Business Progress

04 Nov 2025 8-K: Results of Operations and Financial Condition

Aurinia Pharmaceuticals Reports Financial Results for the Three and Nine Months Ended September 30, 2025 and Provides Update on Recent Business Progress

31 Jul 2025 8-K: Results of Operations and Financial Condition; Other Events

ROCKVILLE, Maryland and EDMONTON, Alberta – July 31, 2025 – Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced financial results for the three and six months ended June 30, 2025.

30 Jun 2025 8-K: Other Events

June 30, 2025 Aritinercept (AUR200) A Dual BAFF/APRIL Inhibitor for the Potential Treatment of Autoimmune Diseases Results from a Phase 1 Study

15 May 2025 8-K: Departure/Election of Directors or Officers; Compensation; Amendments to Articles/Bylaws; Change in Fiscal Year +1 more

Exhibit 3.1 BY-LAW NO. 2 AN AMENDED AND RESTATED GENERAL OPERATING BY-LAW AURINIA PHARMACEUTICALS INC. hereinafter called “the Corporation” SECTION 1 INTERPRETATION 1.1 Definitions In the By-laws of the Corporation, unless the context ot...

12 May 2025 8-K: Results of Operations and Financial Condition

ROCKVILLE, Maryland and EDMONTON, Alberta – May 12, 2025 – Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced financial results for the three months ended March 31, 2025.

27 Feb 2025 8-K: Results of Operations and Financial Condition

Aurinia Pharmaceuticals Reports Financial Results for the Three and Twelve Months Ended December 31, 2024 and Provides Update on Recent Corporate Progress

07 Nov 2024 8-K: Results of Operations and Financial Condition; Costs Associated with Exit or Disposal Activities +1 more

Webcast and conference call to be hosted today at 8:30 a.m. ET

12 Sep 2024 8-K: Departure/Election of Directors or Officers; Compensation; Amendments to Articles/Bylaws; Change in Fiscal Year +1 more

In this By-law of the Corporation, unless the context otherwise requires, terms shall have the meaning ascribed to them in paragraph 15.10. Save as aforesaid, words and expressions defined in the Act have the same meanings when used herein.

01 Aug 2024 8-K: Results of Operations and Financial Condition

ROCKVILLE, Maryland and EDMONTON, Alberta – August 1, 2024 - Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today issued its financial results for the second quarter and six months ended June 30, 2024. Amounts are e...

14 Jun 2024 8-K: Submission of Matters to a Vote of Security Holders

(a)The Company held its annual general meeting of shareholders (the "2024 Meeting") virtually on June 14, 2024.

02 May 2024 8-K: Creation of a Direct Financial Obligation

ROCKVILLE, Maryland and EDMONTON, Alberta – May 2, 2024 - Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today issued its financial results for the first quarter ended March 31, 2024. Amounts are expressed in U.S. d...

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support